Promising drug combo targets tough hodgkin lymphoma cases
NCT ID NCT04938232
First seen Feb 05, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study tests two drugs, ipilimumab and nivolumab, given alone or together, in people with classic Hodgkin lymphoma that has returned or not responded to prior treatments. The goal is to see if these drugs can shrink or control the cancer. About 13 adults with measurable disease are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.